Fuse Vectors
Benjamin Blaha is a highly experienced professional in bioprocess development and management, currently serving as Co-CEO, CTO, and co-founder at Fuse Vectors since August 2022. Prior experience includes holding the Vice President CMC role at ImmuneBridge, where Benjamin set up crucial departments and defined the CMC roadmap. As a consultant for NecstGen, expertise was provided in process development and training in Design of Experiments. Benjamin's tenure at uniQure involved leading a team of fifteen in early-stage CMC projects, while previous roles at the Cell and Gene Therapy Catapult and University College London further solidified skills in manufacturing processes and academic research. Educational qualifications consist of a PhD in Biochemical Engineering from UCL, along with advanced degrees in the same field and a bachelor's degree in Pharmaceutical Sciences.
This person is not in any teams
This person is not in any offices
Fuse Vectors
At Fuse Vectors, our mission is to revolutionize AAV gene therapy development. Traditional cell-based technologies have hindered progress, posing challenges in safety, efficacy, development time, and cost. Our Cell-Free AAV technology surpasses these methods, producing safer, more effective, and cost-efficient AAV viral vectors in a fraction of the time.